Nanna Lüneborg

Nanna is currently at General Partner at Forbion. She focuses on late stage investments from the Forbion Growth Opportunities Fund. She is currently a member of the board of BioInvent (BINV). She has previously served on the board of multiple privately held and publically traded life science companies, including Lava Therapeutics (LVTX), Numab (private), ReViral (acquired by Pfizer), NBE Therapeutics (acquired by Boehringer Ingelheim), ObsEva (OBSV), IO Biotech (IOBT), Inventiva (IVA), Orphazyme (ORPHA), NodThera (private), MinervaX (private), and Stargazer (private). Prior to her role at Forbion, she was with Apposite Capital and Novo Holdings, one of the largest healthcare investors globally, where Nanna was a key member of the European deal team focusing on late-stage biopharma investments across Europe. She holds a PhD in Neuroscience from University College London, MBA from the University of Cambridge and a BA in Physiology and Psychology from the University of Oxford.